EU approves Opdivo for Classical Hodgkin’s Lymphoma
European regulators have expanded the scope of Bristol-Myers Squibb’s immunotherapy Opdivo, approving its use to treat certain patients with Classical Hodgkin Lymphoma (cHL).
Read More
Tag: classical hodgkin’s lymphoma
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
